Skip to main content
Erschienen in: Supportive Care in Cancer 1/2013

01.01.2013 | Original Article

Eliciting patients’ preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment

verfasst von: Nina Lathia, Pierre K. Isogai, Scott E. Walker, Carlo De Angelis, Matthew C. Cheung, Jeffrey S. Hoch, Nicole Mittmann

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

Studies have demonstrated that patients at low risk for febrile neutropenia (FN) complications can be treated safely and effectively at home. Information on patient preferences for outpatient treatment of this condition will help to optimize health care delivery to these patients. The purpose of this study was to elicit non-Hodgkin lymphoma patients’ preferences on attributes related to outpatient treatment of FN.

Methods

We used a self-administered discrete choice experiment questionnaire based on the attributes of out-of-pocket costs, unpaid caregiver time required daily, and probability of return to the hospital. Ten paired scenarios in which levels of the attributes were varied were presented to study patients. For each pair, patients indicated the scenario they preferred. Adjusted odds ratios (ORs) of accepting a scenario that described outpatient care for FN were estimated.

Results

Eighty-eight patients completed the questionnaire. Adjusted ORs [95 % confidence intervals] of accepting outpatient care for FN were 0.84 [0.75, 0.95] for each $10 increase in out-of-pocket cost; 0.82 [0.68, 0.99] for each 1 h increase in daily unpaid caregiver time; and 0.53 [0.50, 0.57] for each 5 % increase in probability of return to the hospital.

Conclusions

Probability of return to the hospital was the most important attribute to patients when considering home-based care for FN. Patients considered out-of-pocket costs and unpaid caregiver time to be less important than probability of return to the hospital. This study identifies factors that could be incorporated into outpatient delivery systems for FN care to ensure adequate patient uptake and satisfaction with such programs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266PubMedCrossRef Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266PubMedCrossRef
2.
Zurück zum Zitat Lathia N, Mittmann N, DeAngelis C et al (2010) Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 116:742–748PubMedCrossRef Lathia N, Mittmann N, DeAngelis C et al (2010) Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 116:742–748PubMedCrossRef
3.
Zurück zum Zitat Cherif H, Johansson E, Bjorkholm M, Kalin M (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91:215–222PubMed Cherif H, Johansson E, Bjorkholm M, Kalin M (2006) The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematologic malignancies. Haematologica 91:215–222PubMed
4.
Zurück zum Zitat Innes H, Lim SL, Hall A et al (2008) Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer 16:485–491PubMedCrossRef Innes H, Lim SL, Hall A et al (2008) Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer 16:485–491PubMedCrossRef
5.
Zurück zum Zitat Innes HE, Smith DB, O'Reilly SM et al (2003) Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer 89:43–49PubMedCrossRef Innes HE, Smith DB, O'Reilly SM et al (2003) Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer 89:43–49PubMedCrossRef
6.
Zurück zum Zitat Klastersky J, Paesmans M, Georgala A et al (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129–4134PubMedCrossRef Klastersky J, Paesmans M, Georgala A et al (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129–4134PubMedCrossRef
7.
Zurück zum Zitat Mizuno T, Katsumata N, Mukai H et al (2007) The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone. Support Care Cancer 15:287–291PubMedCrossRef Mizuno T, Katsumata N, Mukai H et al (2007) The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone. Support Care Cancer 15:287–291PubMedCrossRef
8.
Zurück zum Zitat Rolston KV, Manzullo EF, Elting LS et al (2006) Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules. Cancer 106:2489–2494PubMedCrossRef Rolston KV, Manzullo EF, Elting LS et al (2006) Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules. Cancer 106:2489–2494PubMedCrossRef
9.
Zurück zum Zitat Bennett CL, Calhoun EA (2007) Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 12:478–483PubMedCrossRef Bennett CL, Calhoun EA (2007) Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 12:478–483PubMedCrossRef
10.
Zurück zum Zitat Elting LS, Lu C, Escalante CP et al (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606–611PubMedCrossRef Elting LS, Lu C, Escalante CP et al (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26:606–611PubMedCrossRef
11.
Zurück zum Zitat Hendricks A, Loggers E, Talcott J (2011) Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J Clin Oncol 29:3984–3989PubMedCrossRef Hendricks A, Loggers E, Talcott J (2011) Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J Clin Oncol 29:3984–3989PubMedCrossRef
12.
Zurück zum Zitat Ryan M, Farrar S (2000) Using conjoint analysis to elicit preferences for health care. Brit Med J 320:1530–1533PubMedCrossRef Ryan M, Farrar S (2000) Using conjoint analysis to elicit preferences for health care. Brit Med J 320:1530–1533PubMedCrossRef
13.
Zurück zum Zitat King MT, Hall J, Lancsar E et al (2007) Patient preferences for managing asthma: results from a discrete choice experiment. Health Econ 16:703–717PubMedCrossRef King MT, Hall J, Lancsar E et al (2007) Patient preferences for managing asthma: results from a discrete choice experiment. Health Econ 16:703–717PubMedCrossRef
14.
Zurück zum Zitat Phillips KA, Maddala T, Johnson FR (2002) Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Health Serv Res 37:1681–1705PubMedCrossRef Phillips KA, Maddala T, Johnson FR (2002) Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Health Serv Res 37:1681–1705PubMedCrossRef
15.
Zurück zum Zitat Hauber AB, Johnson FR, Sauriol L, Lescrauwaet B (2005) Risking health to avoid injections: preferences of Canadians with type 2 diabetes. Diabetes Care 28:2243–2245PubMedCrossRef Hauber AB, Johnson FR, Sauriol L, Lescrauwaet B (2005) Risking health to avoid injections: preferences of Canadians with type 2 diabetes. Diabetes Care 28:2243–2245PubMedCrossRef
16.
Zurück zum Zitat Bryan S, Gold L, Sheldon R, Buxton M (2009) Preference measurement using conjoint methods: an empirical investigation of reliability. Health Econ 9:385–395CrossRef Bryan S, Gold L, Sheldon R, Buxton M (2009) Preference measurement using conjoint methods: an empirical investigation of reliability. Health Econ 9:385–395CrossRef
17.
Zurück zum Zitat Ryan M, Watson V, Amaya-Amaya M (2003) Methodological issues in the monetary valuation of benefits in healthcare. Exp Rev Pharmacoecon Outcomes Res 3:717–727CrossRef Ryan M, Watson V, Amaya-Amaya M (2003) Methodological issues in the monetary valuation of benefits in healthcare. Exp Rev Pharmacoecon Outcomes Res 3:717–727CrossRef
19.
Zurück zum Zitat Street DJ, Burgess L, Louviere JL (2005) Quick and easy choice sets: constructing optimal and nearly optimal stated choice experiments. Int J Res Mark 22:459–470CrossRef Street DJ, Burgess L, Louviere JL (2005) Quick and easy choice sets: constructing optimal and nearly optimal stated choice experiments. Int J Res Mark 22:459–470CrossRef
20.
Zurück zum Zitat Dranitsaris G, Tran TM (1995) Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy. Eur J Cancer 31A:2174–2180PubMedCrossRef Dranitsaris G, Tran TM (1995) Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy. Eur J Cancer 31A:2174–2180PubMedCrossRef
21.
Zurück zum Zitat Leese B, Collin R, Clark DJ (1994) The costs of treating febrile neutropenia in patients with malignant blood disorders. PharmacoEconomics 6:233–239PubMedCrossRef Leese B, Collin R, Clark DJ (1994) The costs of treating febrile neutropenia in patients with malignant blood disorders. PharmacoEconomics 6:233–239PubMedCrossRef
22.
Zurück zum Zitat Montero MC, Valdivia ML, Carvajal E et al (1994) Economic study of neutropenia induced by myelotoxic chemotherapy. Pharm World Sci 16:187–192PubMedCrossRef Montero MC, Valdivia ML, Carvajal E et al (1994) Economic study of neutropenia induced by myelotoxic chemotherapy. Pharm World Sci 16:187–192PubMedCrossRef
23.
Zurück zum Zitat Stommel M, Given CW, Bam G (1993) The cost of cancer home care to families. Cancer 71:867–1874CrossRef Stommel M, Given CW, Bam G (1993) The cost of cancer home care to families. Cancer 71:867–1874CrossRef
Metadaten
Titel
Eliciting patients’ preferences for outpatient treatment of febrile neutropenia: a discrete choice experiment
verfasst von
Nina Lathia
Pierre K. Isogai
Scott E. Walker
Carlo De Angelis
Matthew C. Cheung
Jeffrey S. Hoch
Nicole Mittmann
Publikationsdatum
01.01.2013
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 1/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1517-5

Weitere Artikel der Ausgabe 1/2013

Supportive Care in Cancer 1/2013 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.